Formulation development of Lornoxicam loaded heat triggered ocular in-situ gel using factorial design

Basit Öğe Kaydı
dc.authorid0000-0001-5006-3091en_US
dc.authorid0000-0002-7146-326Xen_US
dc.authorid0000-0002-1518-010Xen_US
dc.authorid0000-0002-2249-4668en_US
dc.authorid0000-0002-4713-1249en_US
dc.authorid0000-0003-1786-4449en_US
dc.contributor.authorPolat, Heybet Kerem
dc.contributor.authorÜnal, Sedat
dc.contributor.authorAytekin, Eren
dc.contributor.authorKarakuyu, Nasıf Fatih
dc.contributor.authorPezik, Esra
dc.contributor.authorHaydar, Muhammet Kerim
dc.contributor.authorMokhtare, Behzad
dc.date.accessioned2024-01-12T06:39:54Z
dc.date.available2024-01-12T06:39:54Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Veteriner Fakültesi, Klinik Öncesi Bilimler Bölümü, Patoloji Ana Bilim Dalıen_US
dc.description.abstractObjective: In the current research, lornoxicam-loaded in situ gels were developed, and their potential usage in ocular inflammation was evaluated. Significance: Lornoxicam cyclodextrin complex prepared with hydroxypropyl methylcellulose and poloxamer P407 because of the low viscosity of in situ gels to provide easy application. However, washing and removing it from the ocular surface becomes difficult due to the gelation formation with heat. Methods: A three-level factorial experimental design was used to evaluate the effects of poloxamer 407 concentration, polymer type, and polymer concentration on viscosity, pH, gelation capacity, gelation time, and gelation temperature, which were considered the optimal indicators of lornoxicam-containing formulations. Results: As a result of the three-level factorial experimental design, the optimized formulation contained 15 (%w/v) poloxamer 407 and 1 (%w/v) hydroxypropyl methylcellulose. The optimize formulation viscosity 25 °C = 504 ± 49cP, viscosity 35 °C = 11247 ± 214cP, pH = 6.80 ± 0.01, gelation temprature = 35 ± 0.2 °C, and gelation time= 34 ± 0.2 s was obtained. In the in vitro release studies, 68% of lornoxicam was released with a burst effect in the first three hours; then, the release continued for eight hours with controlled release. Release kinetics of the formulations were modeled mathematically, and it was found to be compatible with the Korsemeyer-Peppas and Weibull models. In cell culture studies, cell viability at 100 µg/mL was 83% and 96% for NL6 and NL6-CD, respectively. In Draize’s in vivo test, no negative conditions occurred in rats. Conclusions: Therefore, the NL6-CD formulation has the potential to be a favorable option for treating ocular inflammation.en_US
dc.identifier.citationPolat, H. K., Ünal, S., Aytekin, E., Karakuyu, N. F., Pezik, E., Haydar, M. K. ve diğerleri. (2023). Formulation development of Lornoxicam loaded heat triggered ocular in-situ gel using factorial design. Drug Development and Industrial Pharmacy, 49(9), 601-615.en_US
dc.identifier.doi10.1080/03639045.2023.2264932
dc.identifier.endpage615en_US
dc.identifier.issn0363-9045
dc.identifier.issue9en_US
dc.identifier.pmid37788164
dc.identifier.scopus2-s2.0-85173734156
dc.identifier.scopusqualityQ1
dc.identifier.startpage601en_US
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/03639045.2023.2264932
dc.identifier.urihttps://hdl.handle.net/11468/13182
dc.identifier.volume49en_US
dc.identifier.wosWOS:001081513800001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorMokhtare, Behzad
dc.language.isoenen_US
dc.publisherTaylor and Francis Ltd.en_US
dc.relation.ispartofDrug Development and Industrial Pharmacy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCell viabilityen_US
dc.subjectCyclodextrinen_US
dc.subjectDraize testen_US
dc.subjectLornoxicamen_US
dc.subjectRelease kineticen_US
dc.titleFormulation development of Lornoxicam loaded heat triggered ocular in-situ gel using factorial designen_US
dc.titleFormulation development of Lornoxicam loaded heat triggered ocular in-situ gel using factorial design
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Formulation development of Lornoxicam loaded heat triggered ocular in-situ gel using factorial design.pdf
Boyut:
2.86 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Klinik Öncesi Bilimler Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu